Evidence map›Paper›PMID 29972754›Full record

ReviewThe New England journal of medicine2018

Chimeric Antigen Receptor Therapy.

Carl H June, Michel Sadelain

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07390071 (Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy), which is not on this map. Cited by 1,350 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,350citing papers in PubMed, 3 pooled it
81.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07390071 narecruitingnot on this mapstarted 2025, after this paper: background citation

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

TypeinterventionalSponsorUniversity of UtahRan2025 to 2029Enrolled40ConditionsLymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity SyndromeArmsHome Automated Telemanagement (HAT) Patient Unit
3 · Its place in the literature

Who cites it

1,350 citing papers in PubMed, 3 syntheses or guidelines pooled it, 2,178 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Recent advances in cell therapy for AML/MDS.International journal of hematology · 2026
    Review
  10. Article
  11. Recent advances in CAR T and CAR NK cell therapy for AML.International journal of hematology · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  20. Review

1,290 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Carl H JuneFrom the Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (C.H.J.); and the Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York (M.S.).ORCID 0000-0003-0241-3557
Michel SadelainFrom the Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (C.H.J.); and the Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York (M.S.).
Memorial Sloan Kettering Cancer Center · US

Funding

Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8M
NCI NIH HHS P01 CA214278
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adoptive TransferAntigens, CD19Genetic EngineeringHumansNeoplasmsReceptors, Antigen, T-CellRecombinant Fusion ProteinsRemission InductionT-LymphocytesAntigens, CD19Receptors, Antigen, T-CellRecombinant Fusion Proteins

Identifiers

PMID29972754
PMCPMC7433347
OpenAlexW2864786814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.